Caplin Steriles, the wholly owned subsidiary of Caplin Point Laboratories, announced that the US FDA has completed inspectionof its Sterile Injectable site at Gummidipoondi between 6 June and 14 June 2019. At theend of this scheduled GMP inspection, there were only two observations. TheCompany believes these to be of procedural in nature and the corrective andpreventive actions for these observations will be presented to the US FDA shortly. Theobservations made were not repeat observations or related to data integrity.
0 thoughts on “USFDA completes inspection of Caplin Sterile Injectable site at Gummidipoondi”